Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab

BACKGROUND: The ECOG-ACRIN Cancer Research Group evaluated rituximab treatment schedules for patients with newly-diagnosed low-tumor-burden follicular-lymphoma (FL). All patients received 4-weekly rituximab treatments as induction therapy. Clinically-responding patients were randomized to receive ri...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Immunother Cancer
Hoofdauteurs: Erbe, Amy K., Wang, Wei, Carmichael, Lakeesha, Hoefges, Anna, Grzywacz, Bartosz, Reville, Patrick K., Ranheim, Erik A., Hank, Jacquelyn A., Kim, KyungMann, Seo, Songwon, Mendonca, Eneida A., Song, Yiqiang, Kenkre, Vaishalee P., Hong, Fangxin, Gascoyne, Randy D., Paietta, Elisabeth, Horning, Sandra J., Miller, Jeffrey S., Kahl, Brad, Sondel, Paul M.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BioMed Central 2019
Onderwerpen:
Research Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6419437/
https://ncbi.nlm.nih.gov/pubmed/30871628
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0538-8
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items